Myopia News Briefs

Johnson & Johnson Vision’s ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management Receive Approval in Canada

September 8, 2021

JACKSONVILLE, Fla. — Johnson & Johnson Vision announced that its ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management have received approval from Health Canada. Abiliti 1-Day lenses are a new option of daily wear, single-use, disposable lenses that have the potential to slow the progression of myopia and are specifically designed for children who are 7 to 12 years old at the start of treatment.§1,3

“The approval from Health Canada for ACUVUE Abiliti 1-Day lenses marks another major step forward in our collaborative efforts with parents and eye care professionals to reshape the future of myopia,” said Xiao-Yu Song, MD, PhD, Global Head of Research & Development, Johnson & Johnson Vision.** “Our researchers and scientists specifically designed Abiliti 1-Day to be a novel soft therapeutic lens with the potential to slow the progression of myopia in children.”1

Abiliti 1-Day lenses are not traditional concentric ring presbyopic design lenses.1 Abiliti 1-Day lenses are a breakthrough innovation specifically designed to slow myopia progression in children and have been shown to reduce axial elongation by 0.105mm on average over a six-month period.††4 The lenses are built from silicone hydrogel (senofilcon A) lens material, the same material as ACUVUE OASYS 1-Day contact lenses, “which have never been beaten in comfort.”*2

Abiliti will provide parents and eye care professionals with a robust and comprehensive set of products for myopia management. Earlier this year, the company also introduced ACUVUE Abiliti Overnight Therapeutic Lenses for Myopia Management in the U.S. Abiliti Overnight lenses are specifically designed and fitted to match a patient’s eye based on its unique corneal shape to temporarily reshape the cornea.5

Abiliti 1-Day lenses are expected to be available in select areas of Canada starting as early as this year and expanding beyond in 2022. Parents and eye care professionals who want more information can visit www.seeyourabiliti.com.

References

* www.clinicaltrials.gov is a website maintained by the NIH. The 4 clinical studies evaluated subjective comfort as a primary or secondary endpoint for ACUVUE OASYS Brand daily disposable family. Review conducted as of April 25, 2021.
† Johnson & Johnson Vision represents the products and services of Johnson & Johnson Surgical Vision, Inc., Johnson & Johnson Vision Care, Inc., and the affiliates of both.
§ Utilizing a smaller lens diameter designed to fit the smaller anatomical features of a pediatric population children (aged 7-12).
** Dr. Xiao-Yu Song, MD, PhD is an employee of Johnson & Johnson Vision Care, Inc., with oversight of Research and Development for both the Surgical Vision and Vision Care organizations.
†† Compared to single vision contact lenses after 6 months wear.
1 JJV Data on file, 2021. Development of Optical Design of ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management.
2 JJV Data on file 2021. Stand-alone Performance Claims; ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management.
3 JJV Data on File 2021. Mechanical Design of ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management- Effect on Fit and Handling.
4 JJV Data on file, 2021. Efficacy of ACUVUE Abiliti 1-Day Soft Therapeutic Lenses for Myopia Management: Comparative Claims vs. Single Vision and Dual Focus Lenses.
5 Data on File 2021. Menicon Design History file.

To Top
  
Subscribe Today Free...
And join more than 25,000 optometric colleagues who have made Review of Optometric Business their daily business advisor.
YOUR EMAIL
FIRST NAME
LAST NAME
  
Subscribe Today Free...
And join more than 25,000 optometric colleagues who have made Review of Optometric Business their daily business advisor.
YOUR EMAIL
FIRST NAME
LAST NAME
Subscribe Today for Free...
Join more than 56,000 of your American & international MD & OD colleagues who have made Review of Myopia Management a key educational resource in the global fight to manage the growing prevalence of myopia.

Subscribe Today for Free...
Join more than 56,000 of your American & international MD & OD colleagues who have made Review of Myopia Management a key educational resource in the global fight to manage the growing prevalence of myopia.